North America Topical Drug Delivery Market is expected to grow with a CAGR of 6.8% in the forecast period of 2023 to 2030. The years considered for the study are as mentioned below.
Access Full Report at @ https://www.databridgemarketresearch.com/jp/reports/north-america-topical-drug-delivery-market
The North America topical drug delivery market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to a favorable market scenario.
The major players in the North America topical drug delivery market are introducing a strong range of products with various applications and adopting strategic initiatives such as announcements, achievements, and innovation into the market. This helped companies to maximize sales with an enhanced services portfolio.
For instance,
- In June 2021, Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, announced that it has entered into an exclusive commercialization and development license agreement with Croma Pharma GmbH, a globally acclaimed pharmaceutical company with specializations in medical aesthetics, ophthalmology and orthopedics for the rights to Pliaglis in nine countries including Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands, and Luxembourg
Crescita Therapeutics Inc is the market leader in North America topical drug delivery market. Some other players in this market are GSK plc., Agile Therapeutics, Pfizer Inc., AbbVie Inc., Viatris Inc., Bayer AG, Procter & Gamble, 3M, Merck & Co., Inc., Bausch Health Companies Inc., Novartis AG, Hisamitsu Pharmaceutical Co.,Inc., Glenmark Pharmaceuticals U.S. Inc., Cipla Inc., Purdue Pharma L.P., Noven Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., NITTO DENKO CORPORATION., Tapemark, tesa Labtec GmbH, LTS Lohmann Therapie-Systeme AG and Medherant Limited among others.
CRESCITA THERAPEUTICS INC.
Crescita Therapeutics Inc is headquartered in Ontario, Canada, and was founded in 2016. It has public ownership. The company focuses on providing a portfolio of prescription and non-prescription products for treating and caring for skin conditions, diseases, and their symptoms. The company has business segments such as Commercial Skincare, Licensing and Royalties, Manufacturing and Services, out of which Commercial Skincare is the market-focused segment. The company has product categories such as Non-Prescription (over-the-counter and in-clinic) and Prescription Products, out of which Non-Prescription (over-the-counter and in-clinic) and Prescription Products is the market-focused category.
For instance,
- In June 2021, Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, announced that it has entered into an exclusive commercialization and development license agreement with Croma Pharma GmbH, a globally acclaimed pharmaceutical company with specializations in medical aesthetics, ophthalmology and orthopedics for the rights to Pliaglis in nine countries including Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg
The company has a presence in North America.
GSK plc.
GSK plc. is headquartered in London, in the U.K., and was founded in 1715. It has public ownership. The company focuses on innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. The company has business segments such as Pharmaceuticals, Vaccines, Consumer Healthcare, out of which pharmaceuticals is the market-focused segment. The company has product categories such as Vaccines, Specialty Medicines, General Medicines, out of which general medicines is the market-focused category.
For instance,
- In December 2022, GSK plc announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patients previously treated with an approved Janus kinase (JAK) inhibitor. Additionally, new analyses from MOMENTUM showed that TI response with momelotinib at week 24 was associated with overall survival
The company has a wide presence in the Americas, Europe, the Middle East and Africa, and Asia-Pacific. The company has subsidiaries such as Action Potential Venture Capital Limited (Canada), Adechsa GmbH (Switzerland), Allen & Hanburys Pharmaceutical Nigeria Limited (Nigeria), Beecham Group p.l.c (England), Beecham Pharmaceuticals (Pte) Limited (Singapore) among others.
Agile Therapeutics
Agile Therapeutics is headquartered in New Jersey, U.S., and was founded in 1997. It has public ownership. The company focuses on fulfilling the unmet needs of today’s women. The product category is Twirla.
For instance,
- In January 2022, Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced a new alliance with Afaxys Pharma, LLC to promote Twirla (levonorgestrel and ethinyl estradiol) transdermal system
The company has a presence in America.
